ClinicalTrials.gg
CompletedNCT06020001Updated Sep 11, 2023

Clinical Evaluation of the AP203 Plant Extract Mixture in Adult Patients With Increased Incidence of Viral and/or Bacterial Upper Respiratory Tract Infections

An interventional study of AP203 mixture (RESCOVIN®) and AP203 mixture (RESCOVIN®) in Upper Respiratory Tract Infection Bacterial, sponsored by AronPharma Sp. z o. o.. Completed at 1 site in Poland. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-11.

Sponsored by AronPharma Sp. z o. o. · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Oct 2022, registered Aug 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Respiratory Tract Infections with a site in Poland — 2 open to participants now, 3 under way, 1 of them phase 3. Respiratory Tract Infections · Poland.

Enrollment
15th of 18
60 · median 154
Started
2022
with 2 others
No phase
5 of 20
none open now
Registered
16th of 20
by date
Lead sponsor
1 of 20
AronPharma Sp. z o. o.

Among the 20 studies in Respiratory Tract Infections with a site in Poland, this one is the 15th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2022, is one of 5 with no phase, and was the 16th registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

2 of the 20 studies in Respiratory Tract Infections with a site in Poland are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 73 Respiratory Tract Infections studies recruiting now, 33 (45%) set no upper age limit and 32 (44%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Respiratory Tract Infections with a site in Poland, or all of them as a file.
02

Study summary

The aim of the study was to assess the efficacy and safety of AP203 preparation (RESCOVIN®) in a group of patients with increased incidence to viral and/or bacterial upper respiratory tract infections.

Read the detailed description

Randomized, double-blind, cross over study conducted under medical supervision on 1) group of 30 patients receiving AP203 mixture in capsule form and 2) group of 30 receiving placebo. After a washout period a group receiving placebo receiver AP203 mixture in syrup form.

The study group was adult patients with an increased incidence of upper respiratory tract infection. During the study, the effect of a mixture of AP203 extracts (RESCOVIN®) on markers of inflammation and oxidative stress and the effect on the incidence of upper respiratory tract infections was assessed.

03

Conditions studied

  • Upper Respiratory Tract Infection Bacterial

Keywords

  • Upper Respiratory Tract Infections
  • Bacterial Infections
  • Viral Infections
  • RESCOVIN
  • Plant extract
  • Chokeberry extract
  • Echinacea extract
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women and men, 18-70 years old
  • Healthy patients at the time of enrollment to the study (without active upper respiratory tract infection)
  • Presence of 2 or more episodes of upper respiratory tract infections or >=2 episodes of cold during the year
  • Patients with chronic upper respiratory tract diseases including bronchial asthma
  • Signed
  • Women: or age

Exclusion criteria

Exclusion Criteria:

  • Intake of supplements containing plant extracts, polyphenols or anthocyanins for the 3 months prior to the study initiation
  • Acute inflammation
  • Oral drugs
  • , anti-allergic drugs in exacerbations of chronic disease at least 2 months from the start of study participation
  • Antibiotic therapy 1 month prior to study initiation
  • Participation in another clinical trial;
  • Oncological disease, disease, severe liver dysfunction, tuberculosis, leukaemia, multiple sclerosis, AIDS, rheumatoid arthritis, organ transplantation;
  • /allergy to any of the ingredients of the product, allergy to plants of the Asteraceae family (e.g. chamomile, calendula);
  • Women who are pregnant or planning to become pregnant during the study period;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    AP203 mixture (RESCOVIN®) in capsule form

    Patients with an increased incidence of upper respiratory tract infection

    Dietary Supplement: AP203 mixture (RESCOVIN®)

  • Experimental
    AP203 mixture (RESCOVIN®) in syrup form

    Patients with an increased incidence of upper respiratory tract infection

    Dietary Supplement: AP203 mixture (RESCOVIN®)

  • Placebo comparator
    Placebo

    Patients with an increased incidence of upper respiratory tract infection

    Other: Placebo

Interventions

  • Dietary supplementAP203 mixture (RESCOVIN®)

    Polyphenol-rich plant extracts Twice a day

  • Dietary supplementAP203 mixture (RESCOVIN®)

    Polyphenol-rich plant extracts Twice a day

  • OtherPlacebo

    Twice a day

06

What researchers measure

Primary outcomes

  1. Efficacy and safety of AP203

    Clinical evaluation of the efficacy and safety of AP203, in a group of patients with an increased incidence of viral and/or bacterial upper respiratory tract infections.

    Time frame: Baseline, 2 months, 4 months, 6 months

Secondary outcomes

  1. hsCRP level

    Comparison of hsCRP level

    Time frame: Baseline, 2 months, 4 months, 6 months

  2. 8-iso-PGF2IsoP level

    Comparison of 8-iso-PGF2IsoP level

    Time frame: Baseline, 2 months, 4 months, 6 months

  3. Cold Intensity Score

    Comparison of Cold Intensity Score (CIS) values

    Time frame: Baseline, 2 months, 4 months, 6 months

07

Study locations

1 site
  • Pomorskie Centrum Reumatologiczne im. dr Jadwigi Titz-Kosko
    Sopot, 81-820, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Apr 2023, 6 months.

Of 27 industry-sponsored interventional studies with no phase under Respiratory Tract Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 6 months is close to that.

Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2023
First posted
Aug 31, 2023
StartActual
Oct 14, 2022
Primary completionActual
Apr 27, 2023
CompletionActual
Apr 27, 2023
Last update
Sep 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06020001
Lead sponsor
AronPharma Sp. z o. o.
Responsible party
Sponsor
First posted
Aug 31, 2023
Start date
Oct 14, 2022
Primary completion
Apr 27, 2023
Completion
Apr 27, 2023
Last update
Sep 11, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion